Table 2.
Effects of Aβ on cultured endothelial cells
Cell Types | Aβ Type | Pre-Aggregated Aβ Used | Concentration Range Tested | Incubation Time | Minimum Concentration Required | Molecular Mechanisms of Aβ | References |
---|---|---|---|---|---|---|---|
HBMEC | Aβ1–42 | Yes | 0.0125–1.25 μM | 1 h | 0.125 μM | Upregulation of C-C chemokine receptor type 5 via JNK, ERK, PI3K activation through RAGE | 109 |
HBMEC | Aβ1–42 | Yes | 0.001–10 μM | 24 h | 0.01 μM | Increased production of hydrogen peroxide through RAGE | 25 |
HBEC | Aβ1–40 | Yes | 1–20 μM | 2, 4, 8, 12 h | 5 μM | Increase in inflammatory markers MCP-1, IL-8, IL-6, GRO via AP-1 transcription | 184 |
MCEC | Aβ25–35 | Yes | 2.5–40 μM | 24 h | 20 μM | Decreased heat shock protein 90, p-Akt, telomerase reverse transcriptase, cyclin-dependent kinase 4 | 29 |
Aβ1–40 | |||||||
MCEC | Aβ25–35 | — | 25 μM | 24 h | 25 μM | Activation of AP-1/pro-apoptotic protein Bim and Smac release | 197 |
MCEC | Aβ25–35 | — | 0.01–50 μM | 24 h | 1 μM | Apoptosis via activation of caspase-8/caspase-3, mitochondrial dysfunction | 194 |
MCEC | Aβ25–35 | Yes | 20 μM | 24 h | 20 μM | Activation of apoptosis signal-regulating kinase 1 leading Bax increase via phosphorylations of p53 and p38-MAPK | 80 |
Rat brain EC | Aβ25–35 | — | 47–380 μM | 72 h | 188 μM | Cell toxicity via increased LDH release and decreased glucose consumption | 149 |
Mouse brain EC line | Aβ1–40 | — | 0.3 μM | 30 min | 0.3 μM | PARP activation via oxidative-nitrosative stress, increase in intracellular Ca2+ | 144 |
BAEC | Aβ1–42 | No | 0.05–2.2 μM | 1–5 min | 0.22 μM | Increased Ca2+-influx | 12 |
BAEC, RMCEC | Aβ1–40 | — | 0.1–1 μM | 30 min | 0.1 μM | Stimulation of cGMP production, release of kinins | 190 |
BAEC | Aβ25–35 | — | 1 μM | 24 h | 1 μM | Impaired activation of K+-channels and reduced nitrite production | 28 |
BAEC | Aβ25–35 | — | 0.1–1000 nM | 24 h | 1 nM | Reduced nitrite production | 150 |
Aβ1–40 | — | 0.1–1000 nM | 24 h | 10 nM | |||
BAEC | Aβ25–35 | Yes | 1 μM | 24 h | 1 μM | Production of reactive oxygen species, blockade of agonist-stimulated eNOS phosphorylation at Ser1179, decreased nitric oxide production | 104 |
Aβ1–42 | 5 μM | 24 h | 5 μM | ||||
HAEC | Aβ25–35 | — | Up to 40 μM | 30 min to 24 h | 5 μM | Apoptosis, necrosis via reactive oxygen species, increase in intracellular Ca2+ | 169 |
Aβ1–42 | Up to 32 μM | 4 μM | |||||
Porcine PAEC | Aβ25–35 | Yes | 1–50 μM | 18 h | 20 μM | Apoptosis, increased free radicals production, dysregulation of Ca2+ homeostasis, impaired glucose uptake | 14 |
24 h | 5 μM |
EC, endothelial cells; HBMEC, human brain microvessel endothelial cells; HBEC, human brain endothelial cells; MCEC, mouse cerebral endothelial cells; BAEC, bovine aortic endothelial cells; RMCEC, rat microvascular coronary endothelial cells; HAEC, human aortic endothelial cells; PAEC, pulmonary aortic endothelial cells; Aβ, amyloid-β; RAGE, receptor for advanced glycation end products; Akt, protein kinase B; MAPK, mitogen-activated protein kinase; AP-1, activator protein 1; JNK, c-Jun NH2-terminal kinase; ERK, extracellular signal-regulated kinase; PI3K, phosphoinositide 3-kinases; MCP-1, monocyte chemoattractant protein-1; IL-6, interleukin-6; IL-8, interleukin-8; GRO, growth-regulated oncogene; LDH, lactate dehydrogenase; eNOS, endothelial nitric oxide synthase; cGMP, cyclic guanosine 3′,5′-monophosphate; -, unknown or not tested.